玻璃体腔注药是年龄相关性黄斑变性、糖尿病视网膜病变、视网膜静脉阻塞等常见慢性眼底病的主要治疗方式，凭借其治疗量大、操作流程化、实施简便，已成为眼科临床常规诊疗项目。基于《“十四五”全国眼健康规划(2021－2025年)》要求，秉承以患者为中心的服务理念，在确保医疗安全的基础上，优化治疗流程，提升患者接受玻璃体腔注药治疗的就诊体验和治疗效果。同时，广东省将有望承接越来越多港澳的眼病患者，需要建立融合粤港澳大湾区的广东省注药标准。因此，在广东省医学会的领导下，由中山大学中山眼科中心联合广东省内其他21所医疗机构共同起草，通过函审、专家论证会等形式，共邀广东省内35名权威专家进行多轮会审，在参考国内外玻璃体腔注药标准的基础上，结合广东省粤港澳大湾区眼科现状，共同讨论最终确定了本标准。本团体标准系统地描述了玻璃体腔注药的基本要求、适应证与禁忌证，制定了全新的玻璃体腔注药标准操作流程及其质量控制标准，并且介绍了并发症或不适的预防及处理，为广东省各级具有资质的医疗机构所开展的玻璃体腔注药的临床应用以及质量评估提供指导。

玻璃体腔注药是年龄相关性黄斑变性、糖尿病视网膜病变、视网膜静脉阻塞等常见慢性眼底病的主要治疗方式，凭借其治疗量大、操作流程化、实施简便，已成为眼科临床常规诊疗项目。基于《“十四五”全国眼健康规划(2021－2025年)》要求，秉承以患者为中心的服务理念，在确保医疗安全的基础上，优化治疗流程，提升患者接受玻璃体腔注药治疗的就诊体验和治疗效果。同时，广东省将有望承接越来越多港澳的眼病患者，需要建立融合粤港澳大湾区的广东省注药标准。因此，在广东省医学会的领导下，由中山大学中山眼科中心联合广东省内其他21所医疗机构共同起草，通过函审、专家论证会等形式，共邀广东省内35名权威专家进行多轮会审，在参考国内外玻璃体腔注药标准的基础上，结合广东省粤港澳大湾区眼科现状，共同讨论最终确定了本标准。本团体标准系统地描述了玻璃体腔注药的基本要求、适应证与禁忌证，制定了全新的玻璃体腔注药标准操作流程及其质量控制标准，并且介绍了并发症或不适的预防及处理，为广东省各级具有资质的医疗机构所开展的玻璃体腔注药的临床应用以及质量评估提供指导。

目的：探讨一站式玻璃体腔注药中心成立前后不同管理模式下的成效，分析其对患者就医时间和就医体验的影响。方法：采用回顾性临床研究。选择2023年1月—2024年3月在汕头大学·香港中文大学联 合汕头国际眼科中心接受玻璃体腔注药的2955例患者纳入研究。将2023年1月—2023年8月玻璃体腔注 药中心成立前接受玻璃体腔注药的1399例患者作为对照组；2023年9月—2024年3月玻璃体腔注药中心成立后接受玻璃体腔注药的1556例患者作为观察组。对照组采用常规日间手术流程，观察组成立一 站式玻璃体腔注药中心，优化诊疗和护理服务流程。通过使用问卷调查比较两组患者就医期间从预约手术、手术当天到术后复查各节点的等待时间、健康教育知晓率、患者满意度及不良事件发生率的差异。结果：问卷调查结果显示，对照组、观察组患者间预约等待手术时间分别为(3.93±2.98) d、 (1.34±2.38) d，手术时间分别为(2.53±2.11) min、(1.93±1.82) min，在院时间分别为(313.62±184.96) min、(85.43±34.14) min，术后复查耗时分别为(45.92±48.44) min、(25.82±16.21) min，差异均有统计学意义(P＜0.001)；患者的总体健康教育知晓率成立前后分别为(95.50%、98.70%)，差异有统计学意义 (χ2 =16.09，P＜0.001)；患者满意度调查结果显示，各项就医体验选项“非常满意”的占比成立后比 成立前明显提高。结论:一站式玻璃体腔注药中心护理模式简化了就医流程，极大地减少了患者就医期 间从预约手术、手术当天到术后复查各节点的等待时间、可显著提升工作效率，明显改善患者整体就 医体验。

To explore the application effects of different nursing models before and after the establishment of a one-stop intravitreal injection center, and to analyze their impact on patient's medical time and experience. Methods: A retrospective clinical study was conducted. From January 2023 to March 2024, 2955 patients who received anti-VEGF drug treatment at the Shantou International Eye Center, a joint initiative of Shantou University and the Chinese University of Hong Kong, were included in the study. The 1399 patients who received anti-VEGF drug treatment before the establishment of the intravitreal injection center from January 2023 to August 2023 were set as the control group; the 1556 patients who received anti-VEGF drug treatment after the establishment of the intravitreal injection center from September 2023 to March 2024 were set as the observation group. The control group followed the routine day surgery process, while the observation group established a one-stop intravitreal injection center to optimize the diagnosis, treatment, and nursing service process. A questionnaire survey was used to compare the differences in waiting time at various points from appointment to surgery, on the day of surgery, and postoperative review, health education awareness rate, patient satisfaction, and adverse event rate between the two groups. Results: The questionnaire survey showed that the waiting time for surgery between the control group and the observation group was (3.93±2.98) d, (1.34±2.38) d, respectively, the surgery time was (2.53±2.11) min, (1.93±1.82) mi, the in-hospital time was (313.62±184.96 min, 85.43±34.14) min, and the postoperative review time was (45.92±48.44) min, (25.82±16.21) min, with all differences being statistically significant (P <0.001); the overall health education awareness rate before and after the establishment was (95.50%, 98.70%), with a significant difference (P <0.001, χ²=16.09); the patient satisfaction survey showed that the proportion of "very satisfied" in various medical experience options was significantly higher after the establishment than before. Conclusions: The one-stop intravitreal injection center nursing model has simplified the medical process, greatly reducing the waiting time at various points from appointment to surgery, on the day of surgery, and postoperative review, significantly improving work efficiency, and significantly improving the overall medical experience of patients.

玻璃体腔注药是年龄相关性黄斑变性、糖尿病视网膜病变、视网膜静脉阻塞等常见慢性眼底病的主要治疗方式，凭借其治疗量大、操作流程化、实施简便，已成为眼科临床常规诊疗项目。基于《“十四五”全国眼健康规划(2021－2025年)》要求，秉承以患者为中心的服务理念，在确保医疗安全的基础上，优化治疗流程，提升患者接受玻璃体腔注药治疗的就诊体验和治疗效果。同时，广东省将有望承接越来越多港澳的眼病患者，需要建立融合粤港澳大湾区的广东省注药标准。因此，在广东省医学会的领导下，由中山大学中山眼科中心联合广东省内其他21所医疗机构共同起草，通过函审、专家论证会等形式，共邀广东省内35名权威专家进行多轮会审，在参考国内外玻璃体腔注药标准的基础上，结合粤港澳大湾区眼科现状，共同讨论最终确定了本标准。本团体标准系统地描述了玻璃体腔注药的基本要求、适应证与禁忌证，制定了全新的玻璃体腔注药标准操作流程及其质量控制标准，并且介绍了并发症或不适的预防及处理，为广东省各级具有资质的医疗机构所开展的玻璃体腔注药的临床应用以及质量评估提供指导。

Intravitreal injection represents the primary method of drug administration for a range of common chronic endophthalmic diseases, including age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. Recognized for its high clinical efficacy, procedural standardization, and operational accessibility, this has become a routine clinical practice in ophthalmology. In alignment with the "National Eye Health Plan during the 14th Five-Year Plan period (2021–2025)" and the patient-centered service philosophy, this approach optimizes treatment processes and enhances patient experience and therapeutic outcomes while ensuring medical safety. Furthermore, Guangdong Province is poised to become a pivotal hub for ophthalmic care within the Guangdong-Hong Kong-Macao Greater Bay Area, anticipating a growing influx of patients from Hong Kong and Macao. This necessitates the development of a unified intravitreal injection standard tailored to regional healthcare integration. Under the auspices of the Guangdong Medical Association, a consortium led by Zhongshan Ophthalmic Center, Sun Yat-sen University, and 21 collaborating medical institutions across Guangdong, formulated this standard. Through iterative reviews involving correspondencebased evaluations and multidisciplinary expert consultations, 35 distinguished specialists refined the standard, synthesizing global best practices with insights into the Greater Bay Area’s unique ophthalmological landscape. This group standard systematically outlines the basic requirements, indications and contraindications of intravitreal injection, establishes a new standard operating procedure for intravitreal injection and quality control standards for this procedure. In addition, we have introduced guidance for the clinical application of this technique and quality assessment, as well as for the prevention and management of complications or adverse reactions.